Results 91 to 100 of about 66,967 (213)

Metastatic model of HPV+ oropharyngeal squamous cell carcinoma demonstrates heterogeneity in tumor metastasis [PDF]

open access: yes, 2016
Human papillomavirus induced (HPV+) cancer incidence is rapidly rising, comprising 60–80% of oropharyngeal squamous cell carcinomas (OPSCCs); while rare, recurrent/metastatic disease accounts for nearly all related deaths.
Coppock, Joseph D   +8 more
core   +2 more sources

BRCA2 interacting proteins [PDF]

open access: yesBreast Cancer Research, 2000
Vidarsson, H   +5 more
openaire   +1 more source

Molecular Alterations in Osteosarcomas of the Oral and Maxillofacial Region: A Scoping Review

open access: yesJournal of Oral Pathology &Medicine, EarlyView.
ABSTRACT Background Given the rarity and aggressive nature of osteosarcomas (OS) in the oral and maxillofacial region, understanding their molecular alterations is essential to improve diagnosis, prognosis, and guide targeted therapies. This study aimed to map molecular alterations associated with oral and maxillofacial OS, providing an overview of the
Iara Vieira Ferreira   +6 more
wiley   +1 more source

Hypersensitivity of BRCA1 heterozygote lymphoblastoid cells to gamma radiation and PARP inhibitors [PDF]

open access: yes, 2013
This article is made available through the Brunel Open Access Publishing Fund. Copyright @ 2013 Bourton EC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use ...
Bourton, EC   +4 more
core   +2 more sources

An Update on Early‐Onset Breast Cancer: Incidence, Risk Factors, Genetic Testing, and Treatment

open access: yesComputational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Early‐onset breast cancer presents in patients typically under the age of 40, while very early‐onset breast cancer is usually viewed as breast cancer occurring before the age of 35. Early‐onset breast cancer demonstrates specific molecular properties and has worse outcomes compared to its late‐onset breast cancer counterpart.
Leila Jahangiri
wiley   +1 more source

Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD‐1 Inhibitor and Niraparib in GErm‐Line‐mutAted Metastatic Breast Cancer

open access: yesMedComm, Volume 7, Issue 4, April 2026.
This phase II trial evaluated the efficacy and safety of niraparib combined with HX008 in metastatic breast cancer (MBC) patients with germline DNA damage response (DDR) gene mutations. This chemotherapy‐free regimen demonstrates promising efficacy and a tolerable safety profile in MBC patients with germline DDR mutations, providing a novel therapeutic
Jian Zhang   +9 more
wiley   +1 more source

Cell cycle-dependent regulation of the bi-directional overlapping promoter of human BRCA2/ZAR2 genes in breast cancer cells [PDF]

open access: yes, 2010
Background BRCA2 gene expression is tightly regulated during the cell cycle in human breast cells. The expression of BRCA2 gene is silenced at the G0/G1 phase of cell growth and is de-silenced at the S/G2 phase.
Smita Misra   +6 more
core   +1 more source

Abnormal Cytokinesis in Cells Deficient in the Breast Cancer Susceptibility Protein BRCA2

open access: yesScience, 2004
Germ-line mutations inactivating BRCA2 predispose to cancer. BRCA2-deficient cells exhibit alterations in chromosome number (aneuploidy), as well as structurally aberrant chromosomes. Here, we show that BRCA2 deficiency impairs the completion of cell division by cytokinesis.
Daniels, Matthew J   +3 more
openaire   +3 more sources

Expanding Access to Genome Sequencing: Higher Diagnostic Yield in Self‐Referred Participants From the CincyKidsSeq Study and Implications for Hybrid Models of Genetic Service Delivery

open access: yesClinical Genetics, Volume 109, Issue 4, Page 717-724, April 2026.
Genome sequencing helped find answers for 1 in 5 children with rare conditions in an outpatient study looking at hybrid genetic care delivery. Families who chose testing themselves had the highest diagnostic yield, showing that self‐referral may be a helpful way to improve access to genetic care.
Kristin Theobald   +10 more
wiley   +1 more source

Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay [PDF]

open access: yes, 2017
Breast cancer risk drastically increases in individuals with a heterozygous germline BRCA1 or BRCA2 mutation, while it is estimated to equal the population risk for relatives without the familial mutation (non-carriers).
Baert, Annelot   +10 more
core   +1 more source

Home - About - Disclaimer - Privacy